Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice

Idiopathic pulmonary fibrosis (IPF) patients have a high risk of developing lung cancer, with few treatment options available. Pirfenidone, an antifibrotic agent approved for the treatment of IPF, has been demonstrated to suppress the TGFβ signaling and modulate the expression of immune-related gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Wan, Zou, Jun, Huang, Yongbiao, Liu, Chaofan, Kang, Yalin, Han, Hu, Tang, Yang, Li, Long, Liu, Bo, Zhao, Weiheng, Yuan, Xianglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781712/
https://www.ncbi.nlm.nih.gov/pubmed/33457101
http://dx.doi.org/10.1080/2162402X.2020.1824631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781712/
https://www.ncbi.nlm.nih.gov/pubmed/33457101
http://dx.doi.org/10.1080/2162402X.2020.1824631

Ejemplares similares